Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report published on Tuesday.

Omeros Price Performance

NASDAQ:OMER traded down $0.25 during mid-day trading on Tuesday, reaching $6.70. The stock had a trading volume of 663,138 shares, compared to its average volume of 460,393. The stock has a market cap of $388.24 million, a P/E ratio of -3.01 and a beta of 1.47. The business’s 50 day moving average is $4.02 and its 200 day moving average is $4.05. Omeros has a fifty-two week low of $1.38 and a fifty-two week high of $7.51.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently modified their holdings of the business. Comerica Bank raised its holdings in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers grew its stake in Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 6,435 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. Cypress Capital Group lifted its holdings in shares of Omeros by 40.0% during the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.